Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1

Molecular and Cellular Endocrinology

Volumn 369, Issue 1-2, 2013, Pages 119-129

  Xiong, Yumei ^a   Swaminath, Gayathri ^a   Cao, Qiong ^a   Yang, Li ^a   Guo, Qi ^a   Salomonis, Heather ^a   Lu, Jenny ^a   Houze, Jonathan B ^a   Dransfield, Paul J ^a   Wang, Yingcai ^a   Liu, Jiwen Jim ^a   Wong, Simon ^a   Schwandner, Ralf ^b   Steger, Franziska ^b   Baribault, Helene ^a   Liu, Lily ^a   Coberly, Suzanne ^a   Miao, Lynn ^a   Zhang, Jane ^a   Lin, Daniel C H ^a   Schwarz, Margrit ^a   more..

^a AMGEN INC   (United States)

^b Amgen Research   (Germany)

Author keywords

Allosterism; FFA1; GLP 1; Type 2 diabetes

Indexed keywords

AEQUORIN; G PROTEIN COUPLED RECEPTOR 40; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INOSITOL PHOSPHATE;

ADIPOCYTE; ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; GLUCAGON-LIKE PEPTIDE 1; INSULIN; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84875054928     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.01.009     Document Type: Article

References (45)

1. Araki T., Hirayama M., Hiroi S., Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2012, 14:271-278.
2. Briscoe C.P., Peat A.J., McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., McCoy D.C., Kenakin T.P., Andrews J.L., Ammala C., Fornwald J.A., Ignar D.M., Jenkinson S. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. British Journal of Pharmacology 2006, 148:619-628.
3. Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K., Eilert M.M., Ellis C., Elshourbagy N.A., Goetz A.S., Minnick D.T., Murdock P.R., Sauls H.R., Shabon U., Spinage L.D., Strum J.C., Szekeres P.G., Tan K.B., Way J.M., Ignar D.M., Wilson S., Muir A.I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. The Journal of Biological Chemistry 2003, 278:11303-11311.
4. Brown S.P., Dransfield P.J., Vimolratana M., Jiao X., Zhu L., Pattaropong V., Sun Y., Liu J., Luo J., Zhang J., Wong S., Zhuang R., Guo Q., Li F., Medina J.C., Swaminath G., Lin D.C.-H., Houze J.B. Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist. ACS Medicinal Chemistry Letters 2012, 3:726-730.
5. Burant C.F., Viswanathan P., Marcinak J., Cao C., Vakilynejad M., Xie B., Leifke E. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012, 379:1403-1411.
6. Christiansen E., Urban C., Grundmann M., Due-Hansen M.E., Hagesaether E., Schmidt J., Pardo L., Ullrich S., Kostenis E., Kassack M., Ulven T. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. Journal of Medicinal Chemistry 2011, 54:6691-6703.
7. Christopoulos A., Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacological Reviews 2002, 54:323-374.
8. Dauqan, E., Sani, H.A., Abdullah, A., Kasim, Z.M., 2011. Fatty acid composition of four different vegetable oils (red palm olein, palm olein, corn oil and coconut oil) by gas chromatography. In: 2nd International Conference on Chemistry and Chemical Engineering. IACSIT Press, Singapore, pp. 31-34.
9. de Ugarte M.T., Portal V.L., Dias A.A., Schaan B.D. Metabolic response to oral lipid overload in diabetes and impaired glucose tolerance. Diabetes Research and Clinical Practice 2005, 69:36-43.
10. Drucker D.J., Brubaker P.L. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:3953-3957.
11. Drucker D.J., Jin T., Asa S.L., Young T.A., Brubaker P.L. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Molecular Endocrinology 1994, 8:1646-1655.
12. Dube P.E., Brubaker P.L. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Hormone and Metabolic Research=Hormon- und Stoffwechselforschung=Hormones et metabolisme 2004, 36:755-760.
13. Edfalk S., Steneberg P., Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
14. Gotoh C., Hong Y.H., Iga T., Hishikawa D., Suzuki Y., Song S.H., Choi K.C., Adachi T., Hirasawa A., Tsujimoto G., Sasaki S., Roh S.G. The regulation of adipogenesis through GPR120. Biochemical and Biophysical Research Communications 2007, 354:591-597.
15. Hara T., Hirasawa A., Ichimura A., Kimura I., Tsujimoto G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. Journal of Pharmaceutical Sciences 2011, 100:3594-3601.
16. Heglind M., Cederberg A., Aquino J., Lucas G., Emfors P., Enerback S. Lack of the central nervous system-and neural crest-expressed forkhead gene Foxs1 affects motor function and body weight. Molecular Cellular Biology 2005, 25:5616-5625.
17. Hemstapat K., de Paulis T., Chen Y., Brady A.E., Grover V.K., Alagille D., Tamagnan G.D., Conn P.J. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Molecular Pharmacology 2006, 70:616-626.
18. Henley C., Yang Y., Davis J., Lu J.Y., Morony S., Fan W., Florio M., Sun B., Shatzen E., Pretorius J.K., Richards W.G., St Jean D.J., Fotsch C., Reagan J.D. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. The Journal of Pharmacology and Experimental Therapeutics 2011, 337:681-691.
19. Herrmann C., Goke R., Richter G., Fehmann H.C., Arnold R., Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995, 56:117-126.
20. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., Sugimoto Y., Miyazaki S., Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nature medicine 2005, 11:90-94.
21. Houze J.B., Zhu L., Sun Y., Akerman M., Qiu W., Zhang A.J., Sharma R., Schmitt M., Wang Y., Liu J., Medina J.C., Reagan J.D., Luo J., Tonn G., Zhang J., Lu J.Y., Chen M., Lopez E., Nguyen K., Yang L., Tang L., Tian H., Shuttleworth S.J., Lin D.C. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorganic & Medicinal Chemistry Letters 2012, 22:1267-1270.
22. Ichimura A., Hirasawa A., Hara T., Tsujimoto G. Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins & Other Lipid Mediators 2009, 89:82-88.
23. Ichimura A., Hirasawa A., Poulain-Godefroy O., Bonnefond A., Hara T., Yengo L., Kimura I., Leloire A., Liu N., Iida K., Choquet H., Besnard P., Lecoeur C., Vivequin S., Ayukawa K., Takeuchi M., Ozawa K., Tauber M., Maffeis C., Morandi A., Buzzetti R., Elliott P., Pouta A., Jarvelin M.R., Korner A., Kiess W., Pigeyre M., Caiazzo R., Van Hul W., Van Gaal L., Horber F., Balkau B., Levy-Marchal C., Rouskas K., Kouvatsi A., Hebebrand J., Hinney A., Scherag A., Pattou F., Meyre D., Koshimizu T.A., Wolowczuk I., Tsujimoto G., Froguel P. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012, 483:350-354.
24. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., Ogi K., Hosoya M., Tanaka Y., Uejima H., Tanaka H., Maruyama M., Satoh R., Okubo S., Kizawa H., Komatsu H., Matsumura F., Noguchi Y., Shinohara T., Hinuma S., Fujisawa Y., Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
25. Kollias-Baker C.A., Ruble J., Jacobson M., Harrison J.K., Ozeck M., Shryock J.C., Belardinelli L. Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor. The Journal of Pharmacology and Experimental Therapeutics 1997, 281:761-768.
26. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochemical and Biophysical Research Communications 2003, 301:406-410.
27. Langmead C.J., Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends in Pharmacological Sciences 2006, 27:475-481.
28. Latour M.G., Alquier T., Oseid E., Tremblay C., Jetton T.L., Luo J., Lin D.C., Poitout V. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56:1087-1094.
29. Lazareno S., Dolezal V., Popham A., Birdsall N.J. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Molecular Pharmacology 2004, 65:257-266.
30. Leach K., Sexton P.M., Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends in Pharmacological Sciences 2007, 28:382-389.
31. Lee T., Schwandner R., Swaminath G., Weiszmann J., Cardozo M., Greenberg J., Jaeckel P., Ge H., Wang Y., Jiao X., Liu J., Kayser F., Tian H., Li Y. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Molecular Pharmacology 2008, 74:1599-1609.
32. Lin D.C., Zhang J., Zhuang R., Li F., Nguyen K., Chen M., Tran T., Lopez E., Lu J.Y., Li X.N., Tang L., Tonn G.R., Swaminath G., Reagan J.D., Chen J.L., Tian H., Lin Y.J., Houze J.B., Luo J. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PloS One 2011, 6:e27270.
33. Lin D., Guo Q., Luo J., Zhang J., Nguyen K., Chen M., Tran T., Dransfield P.J., Brown S.P., Houze J., Vimolratana M., Jiao X.Y., Wang Y., Birdsall N.J., Swaminath G. Identification and pharmacological characterization of multiple allosteric binding sites on the FFA1 receptor. Molecular Pharmacology 2012, 82:843-859.
34. Lindgren O., Carr R.D., Deacon C.F., Holst J.J., Pacini G., Mari A., Ahren B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. The Journal of Clinical Endocrinology and Metabolism 2011, 96:2519-2524.
35. Luo J., Swaminath G., Brown S.P., Zhang J., Guo Q., Chen M., Nguyen K., Tran T., Miao L., Dransfield P.J., Vimolratana M., Houze J., Wong S., Toteva M., Shan B., Li F., Zhang R., Lin D. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 2012, 7:e46300.
36. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., Li P., Lu W.J., Watkins S.M., Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
37. Poitout V. The ins and outs of fatty acids on the pancreatic beta cell. Trends in Endocrinology and Metabolism: TEM 2003, 14:201-203.
38. Reimann F., Habib A.M., Tolhurst G., Parker H.E., Rogers G.J., Gribble F.M. Glucose sensing in L cells: a primary cell study. Cell Metabolism 2008, 8:532-539.
39. Shimpukade B., Hudson B.D., Hovgaard C.K., Milligan G., Ulven T. Discovery of a potent and selective GPR120 agonist. Journal of Medicinal Chemistry 2012, 55:4511-4515.
40. Steneberg P., Rubins N., Bartoov-Shifman R., Walker M.D., Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metabolism 2005, 1:245-258.
41. Swaminath G. Fatty acid binding receptors and their physiological role in type 2 diabetes. Archiv der Pharmazie 2008, 341:753-761.
42. 2+ on the beta2 adrenergic receptor. The Journal of Biological Chemistry 2003, 278:352-356.
43. Swaminath G., Steenhuis J., Kobilka B., Lee T.W. Allosteric modulation of beta2-adrenergic receptor by Zn(2+). Molecular Pharmacology 2002, 61:65-72.
44. Tsujihata Y., Ito R., Suzuki M., Harada A., Negoro N., Yasuma T., Momose Y., Takeuchi K. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. The Journal of Pharmacology and Experimental Therapeutics 2011, 339:228-237.
45. Viswanathan S., Burch J.B.E., Fishman G.I., Moskowitz I.P., Benson D.W. Characterization of sinoatrial node in four conduction system marker mice. Journal of Molecular and Cellular Cardiology 2007, 42:946-953.